
Bonaventura Clotet Sala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8728163/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2016, 316, 171.	7.4	1,076
2	Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet, The, 2014, 383, 2222-2231.	13.7	430
3	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet, The, 2017, 390, 1499-1510.	13.7	391
4	Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine, 2016, 5, 135-146.	6.1	328
5	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV,the, 2015, 2, e127-e136.	4.7	180
6	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. New England Journal of Medicine, 2021, 384, 417-427.	27.0	179
7	Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells. Journal of Immunology, 2014, 193, 1988-1997.	0.8	118
8	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2014, 14, 291-300.	9.1	100
9	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2015, 61, 403-408.	5.8	100
10	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochemical and Biophysical Research Communications, 2021, 538, 187-191.	2.1	86
11	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Scientific Reports, 2021, 11, 2608.	3.3	86
12	Stable neutralizing antibody levels 6Âmonths after mild and severe COVID-19 episodes. Med, 2021, 2, 313-320.e4.	4.4	77
13	Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. Lancet Infectious Diseases, The, 2021, 21, 1365-1372.	9.1	73
14	CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. Nature Communications, 2018, 9, 2739.	12.8	61
15	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 278-288.	10.7	61
16	Detection of a Sexually Transmitted Hepatitis C Virus Protease Inhibitor-Resistance Variant in a Human Immunodeficiency Virus–Infected Homosexual Man. Gastroenterology, 2014, 147, 599-601.e1.	1.3	59
17	Aging in HIV-Infected Subjects: A New Scenario and a New View. BioMed Research International, 2017, 2017, 1-9.	1.9	56
18	Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV,the, 2018, 5, e638-e646.	4.7	56

#	Article	IF	CITATIONS
19	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. Antiviral Therapy, 2005, 10, 791-802.	1.0	55
20	EOSINOPHILIC PUSTULAR FOLLICULITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME. International Journal of Dermatology, 1992, 31, 193-195.	1.0	53
21	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. Antiviral Therapy, 2003, 8, 1-8.	1.0	51
22	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). Journal of Antimicrobial Chemotherapy, 2014, 69, 3368-3371.	3.0	43
23	RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages. Scientific Reports, 2017, 7, 13339.	3.3	43
24	Onceâ€daily dolutegravir is superior to onceâ€daily darunavir/ritonavir in treatmentâ€naÃ⁻ve HIVâ€1â€positive individuals: 96 week results from FLAMINGO. Journal of the International AIDS Society, 2014, 17, 19490.	3.0	41
25	Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. Journal of Antimicrobial Chemotherapy, 2016, 71, 387-394.	3.0	39
26	COVIDApp as an Innovative Strategy for the Management and Follow-Up of COVID-19 Cases in Long-Term Care Facilities in Catalonia: Implementation Study. JMIR Public Health and Surveillance, 2020, 6, e21163.	2.6	39
27	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	3.8	38
28	Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance Testing. Clinical Infectious Diseases, 2014, 59, 578-588.	5.8	38
29	The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells. PLoS Pathogens, 2016, 12, e1005829.	4.7	32
30	SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase Inhibitors. Antimicrobial Agents and Chemotherapy, 2014, 58, 4804-4813.	3.2	30
31	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. PLoS ONE, 2014, 9, e114142.	2.5	27
32	ADAR1 affects HCV infection by modulating innate immune response. Antiviral Research, 2018, 156, 116-127.	4.1	27
33	Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1. Journal of Antimicrobial Chemotherapy, 2014, 69, 1755-1759.	3.0	26
34	Characterization of the Influence of Mediator Complex in HIV-1 Transcription. Journal of Biological Chemistry, 2014, 289, 27665-27676.	3.4	26
35	Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. Journal of Antimicrobial Chemotherapy, 2014, 69, 3057-3060.	3.0	26
36	Approach to amoebic colitis: Epidemiological, clinical and diagnostic considerations in a non-endemic context (Barcelona, 2007-2017). PLoS ONE, 2019, 14, e0212791.	2.5	26

#	Article	IF	CITATIONS
37	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. Journal of Antimicrobial Chemotherapy, 2015, 70, 2104-2107.	3.0	25
38	Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death. Antiviral Therapy, 2003, 8, 155-161.	1.0	25
39	Epidemiological, clinical, diagnostic and economic features of an immigrant population of chronic schistosomiasis sufferers with long-term residence in a non-endemic country (North Metropolitan) Tj ETQq1 1 0.7	′8 4.3 14 rg	B₽‡Overlock
40	Differences in Virological Response to Pegylated Interferon and Ribavirin between Hepatitis C Virus (Hcv)-Monoinfected and HCV–Hiv-Coinfected Patients. Antiviral Therapy, 2008, 13, 1047-1055.	1.0	22
41	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2015, 70, 1139-1145.	3.0	21
42	Classification Models for Neurocognitive Impairment in HIV Infection Based on Demographic and Clinical Variables. PLoS ONE, 2014, 9, e107625.	2.5	19
43	Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men. American Journal of Men's Health, 2017, 11, 647-653.	1.6	19
44	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. Journal of Infectious Diseases, 2015, 211, 936-946.	4.0	18
45	SAMHD1 is active in cycling cells permissive to HIV-1 infection. Antiviral Research, 2017, 142, 123-135.	4.1	18
46	The Aging Imageomics Study: rationale, design and baseline characteristics of the study population. Mechanisms of Ageing and Development, 2020, 189, 111257.	4.6	18
47	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Reports Medicine, 2022, 3, 100523.	6.5	18
48	3′-Azido-2′,3′-Dideoxythymidine (Zidovudine) Uptake Mechanisms in T Lymphocytes. Antiviral Therapy, 2 11, 803-812.	006, 1.0	18
49	Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS ONE, 2017, 12, e0184433.	2.5	17
50	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. Viruses, 2021, 13, 1135.	3.3	17
51	P-glycoprotein (<i>ABCB1</i>) activity decreases raltegravir disposition in primary CD4+P-gp ^{high} cells and correlates with HIV-1 viral load. Journal of Antimicrobial Chemotherapy, 2016, 71, 2782-2792.	3.0	16
52	Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. Translational Lung Cancer Research, 2015, 4, 678-88.	2.8	16
53	Zinc Finger Endonuclease Targeting <i>PSIP1</i> Inhibits HIV-1 Integration. Antimicrobial Agents and Chemotherapy, 2014, 58, 4318-4327.	3.2	15
54	Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 2564-2566.	3.2	15

#	Article	IF	CITATIONS
55	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. PLoS ONE, 2014, 9, e87334.	2.5	15
56	Long-term HIV-1 infection induces an antiviral state in primary macrophages. Antiviral Research, 2016, 133, 145-155.	4.1	14
57	Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors. European Journal of Medicinal Chemistry, 2016, 115, 463-483.	5.5	14
58	Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses. Journal of General Virology, 2006, 87, 1285-1294.	2.9	13
59	Monotherapy with boosted PIs as an ART simplification strategy in clinical practice. Journal of Antimicrobial Chemotherapy, 2015, 70, 1124-1129.	3.0	13
60	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. Journal of Antimicrobial Chemotherapy, 2015, 70, 3087-3095.	3.0	13
61	Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. Scientific Reports, 2017, 7, 3717.	3.3	13
62	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. Scientific Reports, 2017, 7, 40800.	3.3	12
63	Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery. Scientific Reports, 2017, 7, 11711.	3.3	12
64	Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study. PLoS ONE, 2014, 9, e84676.	2.5	11
65	Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2015, 31, 817-821.	1.1	10
66	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 361-371.	0.5	10
67	Self-collected mid-nasal swabs and saliva specimens, compared with nasopharyngeal swabs, for SARS-CoV-2 detection in mild COVID-19 patients. Journal of Infection, 2021, 83, 709-737.	3.3	10
68	Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. Journal of Antimicrobial Chemotherapy, 2015, 70, 1513-1516.	3.0	9
69	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw504.	3.0	9
70	Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. Antiviral Research, 2019, 168, 18-27.	4.1	8
71	Potential prescribing issues among older HIVâ€infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern?. British Journal of Clinical Pharmacology, 2021, 87, 1310-1317.	2.4	8
72	Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients. Antiviral Research, 2015, 114, 48-52.	4.1	7

#	Article	IF	CITATIONS
73	Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity. BioMed Research International, 2016, 2016, 1-5.	1.9	7
74	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. Open Forum Infectious Diseases, 2021, 8, ofab329.	0.9	7
75	Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. Cancers, 2022, 14, 641.	3.7	7
76	Remote Health Monitoring in the Workplace for Early Detection of COVID-19 Cases during the COVID-19 Pandemic Using a Mobile Health Application: COVIDApp International Journal of Environmental Research and Public Health, 2022, 19, 167.	2.6	7
77	Cost–effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 16-20.	0.5	6
78	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. Journal of Antimicrobial Chemotherapy, 2018, 73, 2452-2459.	3.0	6
79	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. Frontiers in Immunology, 2022, 13, 860215.	4.8	6
80	Polymorphisms in <i>LPL</i> , <i>CETP</i> , and <i>HL</i> Protect HIV-Infected Patients from Atherogenic Dyslipidemia in an Allele-Dose-Dependent Manner. AIDS Research and Human Retroviruses, 2015, 31, 882-888.	1.1	5
81	Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series. Clinical Microbiology and Infection, 2021, 27, 651-652.	6.0	5
82	Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. EBioMedicine, 2022, 78, 103956.	6.1	5
83	Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients. BioMed Research International, 2014, 2014, 1-8.	1.9	4
84	Management of bone mineral density in HIV-infected patients. Expert Opinion on Pharmacotherapy, 2016, 17, 845-852.	1.8	4
85	Optimal Use of Transient Elastography and Acoustic Radiation Force Impulse to Stage Liver Fibrosis in HIV/HCVâ€Coinfected Patients in Clinical Practice. Journal of Ultrasound in Medicine, 2018, 37, 113-121.	1.7	4
86	Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1. Expert Opinion on Pharmacotherapy, 2018, 19, 929-934.	1.8	4
87	Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up. International Journal of STD and AIDS, 2019, 30, 56-63.	1.1	4
88	Functional Analyses Reveal Extensive RRE Plasticity in Primary HIV-1 Sequences Selected under Selective Pressure. PLoS ONE, 2014, 9, e106299.	2.5	4
89	Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. PLoS ONE, 2015, 10, e0128131.	2.5	4
90	Modulation of the autophagic pathway inhibits HIV-1 infection in human lymphoid tissue cultured ex vivo. Scientific Reports, 2022, 12, 7439.	3.3	4

#	Article	IF	CITATIONS
91	Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. Future Virology, 2012, 7, 1127-1134.	1.8	3
92	A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. PLoS ONE, 2020, 15, e0238575.	2.5	3
93	Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject. New Microbiologica, 2015, 38, 193-9.	0.1	3
94	Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. Journal of the International AIDS Society, 2014, 17, 19557.	3.0	2
95	Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors. Organic and Biomolecular Chemistry, 2016, 14, 1455-1472.	2.8	2
96	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. Frontiers in Immunology, 2022, 13, .	4.8	2
97	Clinical approach to drug resistance interpretation: expert advice. Current Opinion in HIV and AIDS, 2007, 2, 145-149.	3.8	1
98	Association between lipid genetic and immunological status in chronically HIV-infected patients. Journal of the International AIDS Society, 2014, 17, 19555.	3.0	1
99	Accentuated aging associated with HIV in a Mediterranean setting occurs mainly in persons aged>70 years: a comparative cohort study (Over50 cohort). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, , 1-8.	1.2	1
100	Comparison between mid-nasal swabs and buccal swabs for SARS-CoV-2 detection in mild COVID-19 patients. Journal of Infection, 2022, 84, e78-e79.	3.3	1
101	ADAR1 Function Regulates Innate Immune Activation and Susceptibility to Viral Infections. Proceedings (mdpi), 2020, 50, .	0.2	0
102	Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain. Journal of Virus Eradication, 2015, 1, 211-20.	0.5	0
103	Title is missing!. , 2020, 15, e0238575.		0
104	Title is missing!. , 2020, 15, e0238575.		0
105	Title is missing!. , 2020, 15, e0238575.		0
106	Title is missing!. , 2020, 15, e0238575.		0
107	Prevalence, progression, and management of advanced chronic kidney disease in a cohort of people living with <scp>HIV</scp> . HIV Medicine, 2022, , .	2.2	0